Lee’s Pharma Subsidiary In-Licenses Dyax Drug for China-use
Feb. 6, 2013
Dyax Corp., a developer of novel biotherapeutics and CVie Therapeutics, a subsidiary of Lee's Pharmaceutical, announced a strategic partnership for the development and commercialization of KALBITOR® in the treatment of hereditary angioedema (HAE) and other angioedema indications in China, Hong Kong and KALBITOR is currently marketed in the United States for the treatment of acute attacks of HAE in patients 16 years of age and older.
Under the terms of the exclusive license agreement, Dyax will receive an upfront payment and is eligible to receive future development, regulatory and sales milestones. Dyax is also eligible to receive royalty on net product sales. CVie is solely responsible for all costs associated with development, regulatory activities, and the commercialization of KALBITOR in China, Hong Kong and Macau. Additionally, CVie will purchase drug products from Dyax on a cost-plus basis for commercial supply.